BERBERINE IN METABOLIC DISORDERS: THE “NATURE’S OZEMPIC” PHENOMENON - A NARRATIVE REVIEW
DOI:
https://doi.org/10.31435/ijitss.2(50).2026.5247Keywords:
Berberine, Metabolic Syndrome, Nutraceuticals, Social Media, “Nature’s Ozempic”Abstract
Background: Metabolic disorders, particularly type 2 diabetes and obesity, represent one of the greatest public health challenges of the 21st century. In response to the limitations and side effects of conventional pharmacotherapy, many patients are seeking natural alternatives. Berberine, a traditional medicinal plant compound, has become increasingly popular on social media under the label “Nature’s Ozempic.”
Objective: This narrative review provides a comprehensive synthesis of berberine in metabolic disorders. It examines its molecular mechanisms, clinical evidence, safety profile, pharmacological interactions, and the public health consequences of its rapid rise on social media.
Methods: A targeted literature search was conducted in PubMed, Scopus, Web of Science, and Google Scholar. Priority was given to randomised controlled trials, meta-analyses, mechanistic studies, and recent publications analysing social media trends. The articles published between 2009 and 2026 were primarily included.
Main Findings: Berberine acts through multiple pathways, most notably AMPK activation, modulation of the gut microbiota, and anti-inflammatory effects. Clinical studies show mild but consistent improvements in glycemic control, insulin sensitivity, and lipid parameters, particularly in patients with type 2 diabetes or metabolic syndrome. Its impact on body weight and visceral fat is generally limited. Short-term safety is acceptable, with mainly mild gastrointestinal side effects, although potential interactions with cytochrome P450 enzymes and P-glycoprotein have been documented.
Conclusions: Berberine may serve as a useful adjunctive option in selected patients, but it cannot replace standard therapies such as metformin or statins. Its growing popularity on social media has encouraged widespread self-medication, raising concerns about safety and unrealistic expectations. Larger, longer-term, and more diverse studies are needed to define its true clinical value and long-term safety.
References
Cheng, H., Liu, J., Tan, Y., Feng, W., & Peng, C. (2022). Interactions between gut microbiota and berberine, a necessary procedure to understand the mechanisms of berberine. Journal of Pharmaceutical Analysis, 12(4), 541–555. https://doi.org/10.1016/j.jpha.2021.10.003
Cheng, H., Li, X., Wang, Y., Deng, W., Sun, G., Zhang, D., Hao, J., & Liu, X. (2025). Berberine pharmacological properties and therapeutic potential across cancer, digestive, metabolic, cardiovascular, and neurological diseases: An update review. EXCLI Journal, 24, 1225–1261. https://doi.org/10.17179/excli2025-8771
Cheung, B., Sikand, G., Dineen, E. H., Malik, S., & Barseghian El-Farra, A. (2023). Lipid-lowering nutraceuticals for an integrative approach to dyslipidemia. Journal of Clinical Medicine, 12(10), Article 3414. https://doi.org/10.3390/jcm12103414
Diyab, R., Grgurevic, J., & Roy, R. (2025). Exploring nutrition misinformation on social media platforms. Proceedings of the Nutrition Society, 84(OCE1), Article E8. https://doi.org/10.1017/S0029665125000187
Dong, H., Zhao, Y., Zhao, L., & Lu, F. (2013). The effects of berberine on blood lipids: A systemic review and meta-analysis of randomized controlled trials. Planta Medica, 79(6), 437–446. https://doi.org/10.1055/s-0032-1328321
Evbayekha, E. O., Nwachukwu, E. U., Nikravesh, E., Rosas, V., Onuegbu, C. A., Egwuonwu, O. F., Eguagie, O., Chioma, O. E., Agho, A. V., Samuels, K. A., Willie, A., Nwafor, J. N., Esene-Akhideno, L. N., & Adigun, A. O. (2023). Berberine for adjunct/alternative treatment of dyslipidemia: A literature review. Cureus, 15(5), Article e39261. https://doi.org/10.7759/cureus.39261
Gauch, E. C., & Smollich, M. (2025). Misinformation and disinformation about dietary supplements in social media: Limiting the risks, seizing the opportunities, and shaping structures. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 68(11), 1283–1290. https://doi.org/10.1007/s00103-025-04138-x
Guo, J., Chen, H., Zhang, X., Lou, W., Zhang, P., Qiu, Y., Zhang, C., Wang, Y., & Liu, W. J. (2021). The effect of berberine on metabolic profiles in type 2 diabetic patients: A systematic review and meta-analysis of randomized controlled trials. Oxidative Medicine and Cellular Longevity, 2021, Article 2074610. https://doi.org/10.1155/2021/2074610
Guo, Y., Chen, Y., Tan, Z.-R., Klaassen, C. D., & Zhou, H.-H. (2012). Repeated administration of berberine inhibits cytochromes P450 in humans. European Journal of Clinical Pharmacology, 68(2), 213–217. https://doi.org/10.1007/s00228-011-1108-2
Hu, Y., & Davies, G. E. (2010). Berberine inhibits adipogenesis in high-fat diet-induced obesity mice. Fitoterapia, 81(5), 358–366. https://doi.org/10.1016/j.fitote.2009.10.010
Imenshahidi, M., & Hosseinzadeh, H. (2019). Berberine and barberry (Berberis vulgaris): A clinical review. Phytotherapy Research, 33(3), 504–523. https://doi.org/10.1002/ptr.6252
Kim, W. S., Lee, Y. S., Cha, S. H., Jeong, H. W., Choe, S. S., Lee, M.-R., Oh, G. T., Park, H.-S., Lee, K.-U., Lane, M. D., & Kim, J. B. (2009). Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. American Journal of Physiology-Endocrinology and Metabolism, 296(4), E812–E819. https://doi.org/10.1152/ajpendo.90710.2008
Kong, Y., Yang, H., Nie, R., Zhang, X., Zhang, H., & Nian, X. (2025). Berberine as a multi-target therapeutic agent for obesity: From pharmacological mechanisms to clinical evidence. European Journal of Medical Research, 30(1), Article 477. https://doi.org/10.1186/s40001-025-02738-6
Kwon, M., Lim, D. Y., Lee, C. H., Jeon, J.-H., Choi, M.-K., & Song, I.-S. (2020). Enhanced intestinal absorption and pharmacokinetic modulation of berberine and its metabolites through the inhibition of P-glycoprotein and intestinal metabolism in rats using a berberine mixed micelle formulation. Pharmaceutics, 12(9), Article 882. https://doi.org/10.3390/pharmaceutics12090882
Lei, L., Wang, B., Zhao, L., Li, J., Yan, X., Jiang, J., Wang, L., Ren, G., Li, Y., Cheng, X., Yan, X., Zhu, Y., Guo, Y., Zhong, H., Zhang, H., Li, J., & BRAVO Collaborative Group. (2026). Berberine and adiposity in diabetes-free individuals with obesity and MASLD: A randomized clinical trial. JAMA Network Open, 9(1), Article e2554152. https://doi.org/10.1001/jamanetworkopen.2025.54152
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Jodar, E., Kushner, R. F., Lingvay, I., Mosenzon, O., Ryan, D. H., Rubino, D. M., Wadden, T. A., Wharton, S., & Wilding, J. P. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563
Liu, D., Zhao, H., Zhang, Y., Hu, J., & Xu, H. (2025). Efficacy and safety of berberine on the components of metabolic syndrome: A systematic review and meta-analysis of randomized placebo-controlled trials. Frontiers in Pharmacology, 16, Article 1572197. https://doi.org/10.3389/fphar.2025.1572197
National Institute of Diabetes and Digestive and Kidney Diseases. (2020, October 6). Berberine. In LiverTox: Clinical and research information on drug-induced liver injury. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK564659/
Propfe, L. E., & Seifert, R. (2026). Misrepresentation of semaglutide in social media. Naunyn-Schmiedeberg’s Archives of Pharmacology, 399(1), 815–832. https://doi.org/10.1007/s00210-025-04403-5
Shi, L., Wang, W., Jing, C., Hu, J., & Liao, X. (2025). Berberine and health outcomes: An overview of systematic reviews. BMC Complementary Medicine and Therapies, 25(1), Article 147. https://doi.org/10.1186/s12906-025-04872-4
Singh, A. B., & Liu, J. (2019). Berberine decreases plasma triglyceride levels and upregulates hepatic TRIB1 in LDLR wild type mice and in LDLR deficient mice. Scientific Reports, 9(1), Article 15641. https://doi.org/10.1038/s41598-019-52253-y
Suarez-Lledo, V., & Alvarez-Galvez, J. (2021). Prevalence of health misinformation on social media: Systematic review. Journal of Medical Internet Research, 23(1), Article e17187. https://doi.org/10.2196/17187
Tabeshpour, J., Imenshahidi, M., & Hosseinzadeh, H. (2017). A review of the effects of Berberis vulgaris and its major component, berberine, in metabolic syndrome. Iranian Journal of Basic Medical Sciences, 20(5), 557–568. https://doi.org/10.22038/IJBMS.2017.8682
Wang, H., Zhang, H., Gao, Z., Zhang, Q., & Gu, C. (2022). The mechanism of berberine alleviating metabolic disorder based on gut microbiome. Frontiers in Cellular and Infection Microbiology, 12, Article 854885. https://doi.org/10.3389/fcimb.2022.854885
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
World Health Organization. (2024a, March 1). One in eight people are now living with obesity. https://www.who.int/news/item/01-03-2024-one-in-eight-people-are-now-living-with-obesity
World Health Organization. (2024b, November 13). Urgent action needed as global diabetes cases increase four-fold over past decades. https://www.who.int/news/item/13-11-2024-urgent-action-needed-as-global-diabetes-cases-increase-four-fold-over-past-decades
Wu, W., Xia, Q., Guo, Y., Wang, H., Dong, H., Lu, F., & Yuan, F. (2023). Berberine enhances the function of db/db mice islet β cell through GLP-1/GLP-1R/PKA signaling pathway in intestinal L cell and islet α cell. Frontiers in Pharmacology, 14, Article 1228722. https://doi.org/10.3389/fphar.2023.1228722
Xie, W., Su, F., Wang, G., Peng, Z., Xu, Y., Zhang, Y., Xu, N., Hou, K., Hu, Z., Chen, Y., & Chen, R. (2022). Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis. Frontiers in Pharmacology, 13, Article 1015045. https://doi.org/10.3389/fphar.2022.1015045
Yu, Y., Hao, G., Zhang, Q., Hua, W., Wang, M., Zhou, W., Zong, S., Huang, M., & Wen, X. (2015). Berberine induces GLP-1 secretion through activation of bitter taste receptor pathways. Biochemical Pharmacology, 97(2), 173–177. https://doi.org/10.1016/j.bcp.2015.07.012
Zhang, B., Pan, Y., Xu, L., Tang, D., Dorfman, R. G., Zhou, Q., Yin, Y., Li, Y., Zhou, L., Zhao, S., Zou, X., Wang, L., & Zhang, M. (2018). Berberine promotes glucose uptake and inhibits gluconeogenesis by inhibiting deacetylase SIRT3. Endocrine, 62(3), 576–587. https://doi.org/10.1007/s12020-018-1689-y
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Emilia Lenkiewicz, Alicja Maciejewska, Monika Stępińska, Marta Omiecińska, Maja Kaczor, Weronika Trynkiewicz, Zuzanna Rybka, Julia Żak, Karolina Dąbrowska, Jakub Winiarczyk
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
